Bath & Body Works enters mid-September under pressure on multiple fronts — the stock has shed 11.5% in a week to $16.72, short sellers have rebuilt positions at a pace not seen in months, and the analyst community has spent the past three weeks cutting targets while holding neutral ratings.
Short interest has climbed sharply, rising nearly 19% over the past week to 8.6% of the free float — roughly 17.5 million shares. That's a meaningful move for a name that was sitting closer to 14.7 million shares short just two weeks ago, before the late-August earnings reaction pushed bears back into the trade. The ORTEX short score ticked up from 43 to 46 over the same period, confirming that the signal composite has shifted modestly more bearish. Borrow cost remains low at 0.47%, and availability is extremely loose at over 2,000% — more than enough supply in the lending pool to absorb further short-building without any squeeze mechanics in play. The setup is one of conviction-building rather than crowding: shorts are adding size, but there is no structural pressure forcing covers.
Options traders tell a different story from the short book. The put/call ratio has actually eased this week to 0.65, sitting nearly one standard deviation below its 20-day average of 0.87 — the lower end of the past year's range. After a brief spike into put-heavy territory in late August (PCR hit 1.41 on August 27), options flow has rotated toward calls even as the stock fell. That is a notable divergence: short interest rising while the PCR drops suggests the two communities are leaning in opposite directions on near-term direction.
The Street is firmly in wait-and-see mode. All twelve analyst ratings are Hold equivalents, with a consensus target of $24.20 — roughly 45% above the current price, though that gap reflects how far the stock has fallen rather than fresh conviction. Following the late-August earnings print, multiple firms cut targets in unison: Morgan Stanley trimmed to $20, UBS to $17, and Baird and Barclays both moved lower. Wells Fargo, the sole Overweight, cut to $24 from $26. BMO Capital only initiated at Market Perform this week with a $20 target, underscoring that new coverage is coming in at neutral rather than constructive. The bull case rests on store upgrades, international expansion, and a planned step-up in new product launches in the second half of 2026. Bears point to declining store sales, weak body care performance, and risk that Amazon distribution erodes pricing power without meaningfully lifting volume.
Valuation at these levels looks optically cheap — the stock trades at roughly 6.5x trailing earnings and 6.3x EV/EBITDA — but the EPS momentum scores are weak, ranking in the 21st and 31st percentiles on 30- and 90-day bases respectively. The forward earnings trajectory factor scores near the bottom of the universe. Fidelity (FMR LLC) remains the largest holder at just over 10% of shares, and BlackRock and Vanguard hold combined stakes above 23%. Institutional ownership is concentrated in passive and quant strategies rather than high-conviction active funds — no 13D activist is on the register.
Peers confirm the week's pain is not entirely idiosyncratic. BOBS fell 16.8% on the week, FND lost 3.8%, and WSM dropped 2.8%. Specialty retail broadly sold off, though BBWI's 11.5% decline outpaced most of the basket — suggesting the company-specific narrative around execution and demand carries additional weight beyond the sector headwind. The next scheduled earnings date is November 20, and with the short score drifting higher and short interest re-accumulating post-earnings, the weeks between now and that print are the period worth watching most closely.
See the live data behind this article on ORTEX.
Open BBWI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
